Jaguar Health shares after reverse split, small-cap biotech stock in the OTC market spotlight

Jaguar Health completed a 1-for-75 reverse stock split earlier this week and now trades on the OTC market under the ticker JAGX. The distressed biotech focuses on prescription medicines from plant-based compounds and remains a speculative small-cap name.

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 22:18.

Jaguar Health Inc. (US47010C1053) earlier this week implemented a 1-for-75 reverse stock split and now trades on the OTC market under the ticker JAGX, according to the company's June 24, 2026 investor update and recent SEC filings. The micro-cap gastrointestinal-focused biotech, which had previously been listed on NASDAQ, is trying to maintain market access after its shares failed to meet minimum listing requirements, as reflected in recent coverage by small-cap market commentary sites and OTC market data providers.

Reverse split and OTC relocation

The June 24, 2026 company communication stated that Jaguar Health's board approved the 1-for-75 reverse split effective that day, reducing the number of outstanding shares while proportionally increasing the share price, as described in the investor relations update. The same release confirmed that the stock moved from NASDAQ to the over-the-counter market as of June 25, 2026 due to non-compliance with NASDAQ's minimum bid price rules, a common outcome for distressed biotechs when share prices stay below the exchange's threshold for a sustained period. Jaguar Health investor relations update on the reverse split

Market commentary from US small-cap analysts covering OTC-listed healthcare companies has pointed out that reverse splits of this magnitude often signal attempts to regain institutional visibility rather than operational strength, especially when they follow a long period of share price decline and repeated notices of non-compliance with NASDAQ rules. Recent analysis on micro-cap biotech indices noted that several gastrointestinal and rare disease drug developers have shifted to OTC trading after failing to sustain capital raises on major exchanges, with Jaguar Health cited as an illustrative example alongside other low-liquidity names in the sector.

Peer group and speculative profile

Jaguar Health operates in a crowded biotech field that includes larger gastrointestinal-focused peers such as Ironwood Pharmaceuticals and Takeda, which both maintain established products and stronger balance sheets, according to sector overviews on US healthcare indices. These comparisons underline Jaguar's relatively constrained resources: the company has historically reported limited cash reserves and recurring net losses in quarterly filings, making share-based financing and reverse splits more likely in the absence of substantial revenue growth. Reuters analysis of gastrointestinal-focused biotechs

While mainstream Wall Street houses such as Goldman Sachs or JPMorgan do not cover Jaguar Health, specialty micro-cap research services and online biotech investor communities describe JAGX shares as a high-risk, event-driven instrument. They highlight dependency on a narrow product pipeline, regulatory milestones and licensing deals. Recent consensus snapshots on biotech-focused screening platforms show virtually no formal sell-side coverage, which is typical for OTC-traded micro-caps, but the stock still appears in curated lists of speculative healthcare names watched by retail day traders seeking volatility rather than predictable earnings streams.

What Jaguar Health sells

Jaguar Health's core business centers on prescription medicines derived from plant-based compounds aimed at gastrointestinal conditions, with crofelemer (marketed in the US as Mytesi) as its flagship product for certain diarrhea indications in adults receiving antiretroviral therapy. The company also pursues follow-on indications for supportive care in patients with cancer and other chronic conditions, according to clinical pipeline descriptions in recent corporate presentations and regulatory filings, which detail ongoing studies and post-marketing commitments and position Jaguar as a niche player in symptom management rather than disease-modifying treatments. SEC filing describing crofelemer and Mytesi indications

Where Jaguar Health trades today

As of 2026-06-26, 20:10 UTC, Jaguar Health shares last traded at approximately 1.20 US dollars on the OTC market according to real-time quote data from a leading US over-the-counter trading portal, which also reports very low average daily volume compared with NASDAQ-listed gastrointestinal peers.

Jaguar Health at a glance

• Company: Jaguar Health Inc.
• ISIN: US47010C1053
• WKN: A2QAZM
• Ticker: JAGX
• Trading venue: OTC Market (United States)
• Price (as of 2026-06-26, 20:10): 1.20 USD
• Market cap: approximately 12 million USD (as of 2026-06-26, based on OTC share price and latest reported share count)
• Sector / industry: Health Care - Biotechnology
• Index membership: not a constituent of major indices such as the S&P 500 or NASDAQ-100
• Next earnings date: not officially scheduled

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.